Clinical trial NCT05112536: Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer
Official title: A Phase 2, Open-Label, Single-Arm Study of Single-Dose Lead-In and Neoadjuvant Trilaciclib and Chemotherapy in Patients With Early-Stage Triple Negative Breast Cancer (TNBC)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Triple Negative Breast Cancer
Breast Cancer
Keywords: Breast Cancer
Triple Negative Breast Cancer
CDK4/6 Inhibitor
trilaciclib dihydrochloride
Cosela
Immuno-oncology
Solid tumor
Chemotherapy-induced myelosuppression
Myeloprotective
Cyclin-dependent kinase 4/6 inhibitor
Neoadjuvant
HER2-negative
TNBC
Breast cancer surgery
Trilaciclib
Myeloprotection
pembrolizumab
carboplatin
doxorubicin
cyclophosphamide
Dose-dense anthracycline/cyclophosphamide
paclitaxel
Chemotherapy
Lead sponsor: G1 Therapeutics, Inc.
Sponsor class: INDUSTRY
First posted: 2021-11-09
Enrollment: 24
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the mechanism of action, as well as the safety and efficacy of trilaciclib in combination with standard of care treatment in the neoadjuvant setting of early-stage triple negative breast cancer (TNBC).

This study will have four phases: 1) Screening Phase, 2) Trilaciclib Lead-In Phase, 3) Treatment Phase, and 4) Surgery and Follow-Up Phase. After a screening phase of up to 21 day, each participant will receive trilaciclib single-dose monotherapy during the lead-in phase, followed by a tumor biopsy. During the treatment phase, each participant will receive trilaciclib with standard of care chemotherapy. Immunotherapy may be included during the treatment phase, per standard of care. 3-5 weeks following conclusion of the treatment phase, each participant will undergo definitive surgery. A 30-day Safety Follow-up Visit will occur 30 days after the last dose of trilaciclib and an End of Study Visit will occur within 14 days after definitive surgery.


Eligibility criteria: Inclusion Criteria:

* Suitability of therapy and patient intends to undergo curative surgery
* Documented diagnosis of estrogen receptor (ER)-negative and progesterone receptor (PR)-negative tumor
* Primary tumor ≥ 1.5 cm with any nodal status
* Provide archival tissue for the baseline tissue sample
* ECOG performance status of 0 or 1
* Demonstrates adequate organ function
* Research tumor biopsies including at least one on-treatment biopsy (and additional biopsy at baseline, if required)
* Participants of child bearing potential must be willing to use 2 forms of contraception during the study and for 6 months following study treatment

Exclusion Criteria:

* Prior systemic therapies or radiation for current breast cancer
* History of invasive malignancy ≤3 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
* History of breast cancer including ipsilateral ductal carcinoma in situ (DCIS) treated with radiotherapy at any time
* Previous exposure to doxorubicin of more than 200 mg/m2 (as lifetime exposure to doxorubicin is not to exceed 450 mg/m2)
* For patients who will receive pembrolizumab:

  * History of active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy is not considered a form of systemic treatment
  * Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drugs
* History of (non-infectious) pneumonitis that required steroids or current pneumonitis
* Known history of active tuberculosis (Bacillus Tuberculosis)
* History of severe hepatic impairment
* Uncontrolled ischemic heart disease or uncontrolled symptomatic congestive heart failure (Class II-IV as defined by the New York Heart Association \[NYHA\] functional classification system)
* Known history of stroke, cerebrovascular accident, severe/unstable angina, myocardial infarction, or coronary angioplasty/stenting/bypass grafting within 6 months prior to enrollment
* Known serious active infection (e.g., human immunodeficiency virus \[HIV\], hepatitis B or C, tuberculosis).
* Women who are pregnant or breastfeeding
* Participation in other studies involving active treatment with investigational drug(s)
* Prior hematopoietic stem cell or bone marrow transplantation

Primary outcomes:
measure: Immune-based Mechanism of Action
timeFrame: Up to 8 days after lead-in trilaciclib dose
Secondary outcomes:
measure: Pathologic Complete Response (pCR) Rate
timeFrame: Up to 26 weeks
measure: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)
timeFrame: Up to 28 weeks
Other outcomes:
Locations:
city: Los Alamitos
country: United States
facility: Cancer and Blood Specialty Clinic
state: California
city: Santa Monica
country: United States
facility: UCLA Department of Medicine - Hematology/Oncology
state: California
city: Whittier
country: United States
facility: PIH Health
state: California
city: Lincoln
country: United States
facility: Nebraska Hematology-Oncology, P.C.
state: Nebraska
city: Durham
country: United States
facility: Duke University Medical Center
state: North Carolina
city: Dallas
country: United States
facility: Texas Oncology - Baylor Charles A. Sammons Cancer Center
state: Texas
city: Norfolk
country: United States
facility: Virginia Oncology Associates
state: Virginia
Study officials:
References: